Viral vectors are important tools for incorporating genetic material into cells, making them invaluable in studying gene function, disease mechanisms, and potential therapies. Non-human primates are crucial models for clinical research due to their genetic and physiological similarity to humans.
As research in gene therapy & gene-modified cell therapies, vaccine development, and regenerative medicine expands, the demand for effective viral vectors tailored for NHP (non-human primates) studies is anticipated to grow significantly, supporting the development of innovative therapeutic solutions and fueling the viral vectors for non-human primates market size.
The global viral vectors for non-human primates market is characterized by a broad group of established biotechnology companies, academic institutions, and emerging startups.
Key players have the advantage of infrastructure and expertise, while startups may innovate more rapidly but face issues in scaling production and gaining market acceptance.
Viral vectors are used for various applications in medical biotechnology and biological sciences such as medication and gene delivery, vaccinations/nanocarriers, and oncolytics. Viral vectors are utilized as vehicles for the delivery of therapeutic substrate in a variety of therapeutic and diagnostic applications.
The technology's potential benefits over conventional modalities have long piqued curiosity. Genetic or chemical alterations of viruses to create novel viral mutants have an unmatched advantage.
Gene treatments via viral vectors inject specific DNA sequences encoding genes, RNAs, or other therapeutic substrates into cells using modified viruses as drug delivery vehicles.
| Attribute | Detail |
|---|---|
| Drivers |
|
Gene therapy is gaining attention and funding as a possible treatment for a number of inherited and acquired disorders. Viral vectors are an indispensable part of gene therapy in order to transfer therapeutic genes into target cells.
The approval process for gene and cell therapies is still expanding, with 10% of all innovative approvals by the U.S. FDA in 2023 being cell and gene therapies (CGTs), up from 7% and 6% in 2022 and 2021, respectively.
There is a lot of momentum heading into 2024 and beyond with a surge in number of ground-breaking approvals, such the first CRISPR-based treatment authorized for marketing in the U.S.
Of all gene, cell, and RNA therapies, 2,093 (including genetically modified cell therapies such as CAR-T cell therapies) are still in the research and development stage. As of Q1 2024, 35 gene and gene-modified cell therapies are currently in phase III clinical trials.
Further, 282 gene and gene-modified cell therapies are under evaluation in phase II clinical trials, while 301 studies are in phase I clinical study. Moreover, 1471 therapies are in preclinical developmental stage.
CAR-T cell therapies represent the most common technology used in the pipeline of genetically modified cell therapies (preclinical through to pre-registration), representing 52% of the pipeline, followed by other categories such as TCR-NK, CAR-M, and TAC-T therapies.
Thus, the advancing pipeline of gene therapies and gene-modified cell therapies is driving the viral vectors for non-human primates market demand, with the surge in need for preclinical research.
The potential uses of gene therapy have increased due to developments in the understanding of genetic illnesses and the creation of focused medicines. Therapeutic genes can now be precisely delivered and expressed thanks to viral vectors, improving the efficacy of treatment for illnesses that were previously incurable or challenging to control.
Adeno-associated virus (AAV), lentivirus, and herpes simplex virus are the three types of viral vectors that the US FDA has approved for use in eight different therapeutic applications. Originally designed to treat uncommon illnesses, these treatments are now being used to treat more prevalent ailments.
As of February 2022, there were 120 viral-vector medicines during Phase II studies and 25 in late-stage development. This pipeline is anticipated to continue expanding.
Viral vectors are highly versatile for treating a variety of disorders because they have the ability to programmatically change gene expression.
By replacing genes, they can treat uncommon monogenic diseases, and by managing gene expression, they can treat diseases that affect a larger population. Thus, the numerous therapeutic applications are bolstering the viral vectors for non-human primates market growth.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the viral vectors for non-human primates industry analysis, North America dominates the landscape. North America accounted for nearly 48.3% of the viral vectors for non-human primates market share in 2023.
The U.S. is a hub of biotechnology and pharmaceutical innovation. The country has a robust network of biotechnology and pharmaceutical companies, research institutions, and academic centers focused on viral vector technology. These entities drive innovation and development in the field.
In March 2022, Mass Eye and Ear, the flagship research and teaching hospital of the Harvard Medical School Department of Ophthalmology, demonstrated that the viral vector Anc80L65 effectively delivered genetic material into the inner ears of nonhuman primates using a specialized surgical technique.
This breakthrough sets the stage for advancing this method into clinical trials aimed at developing treatments for hearing loss and vestibular disorders.
According to the viral vectors for non-human primates industry report, the global market is fragmented with the presence of a number of players. Companies are engaging in partnerships and collaborations to gain a strong foothold in the viral vectors for non-human primates market.
Lonza, Thermo Fisher Scientific Inc., Revvity, VectorBuilder Inc., Creative Biolabs, Takara Bio Inc., Merck KGaA, Andelyn Biosciences, Biovian Oy, and Genezen are the prominent viral vectors for non-human primates market manufacturers.
Each of these players has been profiled in the viral vectors for non-human primates market research report based on various parameters including company overview, business segments, product portfolio, recent developments, business strategies, and financial overview.
| Attribute | Detail |
|---|---|
| Size in 2023 | US$ 145.8 Mn |
| Forecast Value in 2034 | More than US$ 429.9 Mn |
| CAGR | 10.5% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Mn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 145.8 Mn in 2023
It is projected to reach more than US$ 429.9 Mn by the end of 2034
The CAGR is anticipated to be 10.5% from 2024 to 2034
North America is expected to account for the largest share from 2024 to 2034
Lonza, Thermo Fisher Scientific Inc., Revvity, VectorBuilder Inc., Creative Biolabs, Takara Bio Inc., MERCK KGaA, Andelyn Biosciences, Biovian Oy, and Genezen
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Viral Vectors for Non-human Primates Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, 2020-2034
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Recent Advancements in Viral Vector Technology
5.2. Porter’s Five Forces Analysis
5.3. List of Leading CROs Offering Non-human Primate based Preclinical Testing Services
5.4. PESTLE Analysis
5.5. Key Industry Events (Product Approvals, Partnerships, and Collaborations)
6. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By Vector Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Vector Type, 2020-2034
6.3.1. Adenoviral Vectors
6.3.2. Adeno-associated Vectors
6.3.3. Retroviral Vectors
6.3.4. Lentiviral Vectors
6.3.5. Others
6.4. Market Attractiveness By Vector Type
7. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By Type of Non-human Primates
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
7.3.1. Marmosets
7.3.2. Rhesus macaques
7.3.3. Cynomolgus monkey
7.3.4. Others
7.4. Market Attractiveness By Type of Non-human Primates
8. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By Application
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Application, 2020-2034
8.3.1. Gene Therapy
8.3.2. Vaccine Research
8.4. Market Attractiveness By Application
9. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By Therapeutic Area
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Therapeutic Area, 2020-2034
9.3.1. Genetic Disorders
9.3.2. Infectious Diseases
9.3.3. Oncological Disorders
9.3.4. Others
9.4. Market Attractiveness By Therapeutic Area
10. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By End-user
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast By End-user, 2020-2034
10.3.1. Pharmaceutical and Biotechnology Companies
10.3.2. Academic and Research Institutions
10.4. Market Attractiveness By End-user
11. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By Region
11.1. Key Findings
11.2. Market Value Forecast By Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness By Region
12. North America Viral Vectors for Non-human Primates Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Vector Type, 2020-2034
12.2.1. Adenoviral Vectors
12.2.2. Adeno-associated Vectors
12.2.3. Retroviral Vectors
12.2.4. Lentiviral Vectors
12.2.5. Others
12.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
12.3.1. Marmosets
12.3.2. Rhesus macaques
12.3.3. Cynomolgus monkey
12.3.4. Others
12.4. Market Value Forecast By Application, 2020-2034
12.4.1. Gene Therapy
12.4.2. Vaccine Research
12.5. Market Value Forecast By Therapeutic Area, 2020-2034
12.5.1. Genetic Disorders
12.5.2. Infectious Diseases
12.5.3. Oncological Disorders
12.5.4. Others
12.6. Market Value Forecast By End-user, 2020-2034
12.6.1. Pharmaceutical and Biotechnology Companies
12.6.2. Academic and Research Institutions
12.7. Market Value Forecast By Country, 2020-2034
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Vector Type
12.8.2. By Type of Non-human Primates
12.8.3. By Application
12.8.4. By Therapeutic Area
12.8.5. By End-user
12.8.6. By Country
13. Europe Viral Vectors for Non-human Primates Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Vector Type, 2020-2034
13.2.1. Adenoviral Vectors
13.2.2. Adeno-associated Vectors
13.2.3. Retroviral Vectors
13.2.4. Lentiviral Vectors
13.2.5. Others
13.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
13.3.1. Marmosets
13.3.2. Rhesus macaques
13.3.3. Cynomolgus monkey
13.3.4. Others
13.4. Market Value Forecast By Application, 2020-2034
13.4.1. Gene Therapy
13.4.2. Vaccine Research
13.5. Market Value Forecast By Therapeutic Area, 2020-2034
13.5.1. Genetic Disorders
13.5.2. Infectious Diseases
13.5.3. Oncological Disorders
13.5.4. Others
13.6. Market Value Forecast By End-user, 2020-2034
13.6.1. Pharmaceutical and Biotechnology Companies
13.6.2. Academic and Research Institutions
13.7. Market Value Forecast By Country, 2020-2034
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Spain
13.7.5. Italy
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Vector Type
13.8.2. By Type of Non-human Primates
13.8.3. By Application
13.8.4. By Therapeutic Area
13.8.5. By End-user
13.8.6. By Country
14. Asia Pacific Viral Vectors for Non-human Primates Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Vector Type, 2020-2034
14.2.1. Adenoviral Vectors
14.2.2. Adeno-associated Vectors
14.2.3. Retroviral Vectors
14.2.4. Lentiviral Vectors
14.2.5. Others
14.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
14.3.1. Marmosets
14.3.2. Rhesus macaques
14.3.3. Cynomolgus monkey
14.3.4. Others
14.4. Market Value Forecast By Application, 2020-2034
14.4.1. Gene Therapy
14.4.2. Vaccine Research
14.5. Market Value Forecast By Therapeutic Area, 2020-2034
14.5.1. Genetic Disorders
14.5.2. Infectious Diseases
14.5.3. Oncological Disorders
14.5.4. Others
14.6. Market Value Forecast By End-user, 2020-2034
14.6.1. Pharmaceutical and Biotechnology Companies
14.6.2. Academic and Research Institutions
14.7. Market Value Forecast By Country, 2020-2034
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Vector Type
14.8.2. By Type of Non-human Primates
14.8.3. By Application
14.8.4. By Therapeutic Area
14.8.5. By End-user
14.8.6. By Country
15. Latin America Viral Vectors for Non-human Primates Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Vector Type, 2020-2034
15.2.1. Adenoviral Vectors
15.2.2. Adeno-associated Vectors
15.2.3. Retroviral Vectors
15.2.4. Lentiviral Vectors
15.2.5. Others
15.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
15.3.1. Marmosets
15.3.2. Rhesus macaques
15.3.3. Cynomolgus monkey
15.3.4. Others
15.4. Market Value Forecast By Application, 2020-2034
15.4.1. Gene Therapy
15.4.2. Vaccine Research
15.5. Market Value Forecast By Therapeutic Area, 2020-2034
15.5.1. Genetic Disorders
15.5.2. Infectious Diseases
15.5.3. Oncological Disorders
15.5.4. Others
15.6. Market Value Forecast By End-user, 2020-2034
15.6.1. Pharmaceutical and Biotechnology Companies
15.6.2. Academic and Research Institutions
15.7. Market Value Forecast By Country, 2020-2034
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Vector Type
15.8.2. By Type of Non-human Primates
15.8.3. By Application
15.8.4. By Therapeutic Area
15.8.5. By End-user
15.8.6. By Country
16. Middle East & Africa Viral Vectors for Non-human Primates Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast By Vector Type, 2020-2034
16.2.1. Adenoviral Vectors
16.2.2. Adeno-associated Vectors
16.2.3. Retroviral Vectors
16.2.4. Lentiviral Vectors
16.2.5. Others
16.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
16.3.1. Marmosets
16.3.2. Rhesus macaques
16.3.3. Cynomolgus monkey
16.3.4. Others
16.4. Market Value Forecast By Application, 2020-2034
16.4.1. Gene Therapy
16.4.2. Vaccine Research
16.5. Market Value Forecast By Therapeutic Area, 2020-2034
16.5.1. Genetic Disorders
16.5.2. Infectious Diseases
16.5.3. Oncological Disorders
16.5.4. Others
16.6. Market Value Forecast By End-user, 2020-2034
16.6.1. Pharmaceutical and Biotechnology Companies
16.6.2. Academic and Research Institutions
16.7. Market Value Forecast By Country, 2020-2034
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Vector Type
16.8.2. By Type of Non-human Primates
16.8.3. By Application
16.8.4. By Therapeutic Area
16.8.5. By End-user
16.8.6. By Country
17. Competition Landscape
17.1. Market Player - Competition Matrix (By Tier and Size of companies)
17.2. Market Share Analysis By Company (2023)
17.3. Market Footprint Analysis
17.3.1. By Region
17.3.2. By Vector Type
17.4. Competitive Snapshot
17.5. Company Profiles
17.5.1. Lonza
17.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.5.1.2. Product Portfolio
17.5.1.3. Financial Overview
17.5.1.4. SWOT Analysis
17.5.1.5. Strategic Overview
17.5.2. Thermo Fisher Scientific Inc
17.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.5.2.2. Product Portfolio
17.5.2.3. Financial Overview
17.5.2.4. SWOT Analysis
17.5.2.5. Strategic Overview
17.5.3. Revvity
17.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.5.3.2. Product Portfolio
17.5.3.3. Financial Overview
17.5.3.4. SWOT Analysis
17.5.3.5. Strategic Overview
17.5.4. VectorBuilder Inc.
17.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.5.4.2. Product Portfolio
17.5.4.3. Financial Overview
17.5.4.4. SWOT Analysis
17.5.4.5. Strategic Overview
17.5.5. Creative Biolabs
17.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.5.5.2. Product Portfolio
17.5.5.3. Financial Overview
17.5.5.4. SWOT Analysis
17.5.5.5. Strategic Overview
17.5.6. Takara Bio Inc
17.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.5.6.2. Product Portfolio
17.5.6.3. Financial Overview
17.5.6.4. SWOT Analysis
17.5.6.5. Strategic Overview
17.5.7. MERCK KGaA
17.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.5.7.2. Product Portfolio
17.5.7.3. Financial Overview
17.5.7.4. SWOT Analysis
17.5.7.5. Strategic Overview
17.5.8. Andelyn Biosciences
17.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.5.8.2. Product Portfolio
17.5.8.3. Financial Overview
17.5.8.4. SWOT Analysis
17.5.8.5. Strategic Overview
17.5.9. Biovian Oy
17.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.5.9.2. Product Portfolio
17.5.9.3. Financial Overview
17.5.9.4. SWOT Analysis
17.5.9.5. Strategic Overview
17.5.10. Genezen
17.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.5.10.2. Product Portfolio
17.5.10.3. Financial Overview
17.5.10.4. SWOT Analysis
17.5.10.5. Strategic Overview
List of Tables
Table 1: Global Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Vector Type, 2020-2034
Table 2: Global Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Type of Non-human Primates, 2020-2034
Table 3: Global Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Application, 2020-2034
Table 4: Global Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
Table 5: Global Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 6: Global Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Region, 2020-2034
Table 7: North America Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Country, 2020-2034
Table 8: North America Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Vector Type, 2020-2034
Table 9: North America Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Type of Non-human Primates, 2020-2034
Table 10: North America Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Application, 2020-2034
Table 11: North America Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
Table 12: North America Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 13: Europe Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Europe Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Vector Type, 2020-2034
Table 15: Europe Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Type of Non-human Primates, 2020-2034
Table 16: Europe Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Application, 2020-2034
Table 17: Europe Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
Table 18: Europe Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Application, 2020-2034
Table 19: Europe Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 20: Asia Pacific Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 21: Asia Pacific Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Vector Type, 2020-2034
Table 22: Asia Pacific Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Type of Non-human Primates, 2020-2034
Table 23: Asia Pacific Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Application, 2020-2034
Table 24: Asia Pacific Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
Table 25: Asia Pacific Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 26: Latin America Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 27: Latin America Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Vector Type, 2020-2034
Table 28: Latin America Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Type of Non-human Primates, 2020-2034
Table 29: Latin America Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Application, 2020-2034
Table 30: Latin America Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
Table 31: Latin America Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 32: Middle East & Africa Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 33: Middle East & Africa Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Vector Type, 2020-2034
Table 34: Middle East & Africa Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Type of Non-human Primates, 2020-2034
Table 35: Middle East & Africa Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Application, 2020-2034
Table 36: Middle East & Africa Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
Table 37: Middle East & Africa Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast, by End-user, 2020-2034
List of Figures
Figure 1: Global Viral Vectors for Non-human Primates Market Value (US$ Mn) Forecast, 2020-2034
Figure 2: Global Viral Vectors for Non-human Primates Market Value Share, by Vector Type, 2023
Figure 3: Global Viral Vectors for Non-human Primates Market Value Share, by Type of Non-human Primates, 2023
Figure 4: Global Viral Vectors for Non-human Primates Market Value Share, by Application, 2023
Figure 5: Global Viral Vectors for Non-human Primates Market Value Share, by Therapeutic Area, 2023
Figure 6: Global Viral Vectors for Non-human Primates Market Value Share, by End-user, 2023
Figure 7: Global Viral Vectors for Non-human Primates Market Value Share, by Region, 2023
Figure 8: Global Viral Vectors for Non-human Primates Market Value (US$ Mn) Share Analysis, by Vector Type, 2023 and 2034
Figure 9: Global Viral Vectors for Non-human Primates Market Share Analysis, by Vector Type, 2023
Figure 10: Global Viral Vectors for Non-human Primates Market Share Analysis, by Vector Type, 2034
Figure 11: Global Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Vector Type, 2024-2034
Figure 12: Global Viral Vectors for Non-human Primates Market Value (US$ Mn), by Adenoviral Vectors, 2020-2034
Figure 13: Global Viral Vectors for Non-human Primates Market Value Share Analysis, by Adenoviral Vectors, 2023 and 2034
Figure 14: Global Viral Vectors for Non-human Primates Market Value (US$ Mn), by Adeno-associated Vectors, 2020-2034
Figure 15: Global Viral Vectors for Non-human Primates Market Value Share Analysis, by Adeno-associated Vectors, 2023 and 2034
Figure 16: Global Viral Vectors for Non-human Primates Market Value (US$ Mn), by Retroviral, 2020-2034
Figure 17: Global Viral Vectors for Non-human Primates Market Value Share Analysis, by Retroviral, 2023 and 2034
Figure 18: Global Viral Vectors for Non-human Primates Market Value (US$ Mn), by Others, 2020-2034
Figure 19: Global Viral Vectors for Non-human Primates Market Value Share Analysis, by Others, 2023 and 2034
Figure 20: Global Viral Vectors for Non-human Primates Market Value (US$ Mn), by Others, 2020-2034
Figure 21: Global Viral Vectors for Non-human Primates Market Value Share Analysis, by Others, 2023 and 2034
Figure 22: Global Viral Vectors for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Non-human Primates, 2023 and 2034
Figure 23: Global Viral Vectors for Non-human Primates Market Share Analysis, by Type of Non-human Primates, 2023
Figure 24: Global Viral Vectors for Non-human Primates Market Share Analysis, by Type of Non-human Primates, 2034
Figure 25: Global Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Type of Non-human Primates, 2024-2034
Figure 26: Global Viral Vectors for Non-human Primates Market Value (US$ Mn), by Marmosets, 2020-2034
Figure 27: Global Viral Vectors for Non-human Primates Market Value Share Analysis, by Marmosets, 2023 and 2034
Figure 28: Global Viral Vectors for Non-human Primates Market Value (US$ Mn), by Rhesus Macaques, 2020-2034
Figure 29: Global Viral Vectors for Non-human Primates Market Value (US$ Mn), by Rhesus Macaques, 2020-2034
Figure 30: Global Viral Vectors for Non-human Primates Market Value (US$ Mn), by Cynomolgus monkey, 2020-2034
Figure 31: Global Viral Vectors for Non-human Primates Market Value Share Analysis, by Cynomolgus Monkey, 2023 and 2034
Figure 32: Global Viral Vectors for Non-human Primates Market Value (US$ Mn), by Others, 2020-2034
Figure 33: Global Viral Vectors for Non-human Primates Market Value Share Analysis, by Others, 2023 and 2034
Figure 34: Global Viral Vectors for Non-human Primates Market Value (US$ Mn) Share Analysis, by Application, 2023 and 2034
Figure 35: Global Viral Vectors for Non-human Primates Market Share Analysis, by Application, 2023
Figure 36: Global Viral Vectors for Non-human Primates Market Share Analysis, by Application, 2034
Figure 37: Global Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Application, 2024-2034
Figure 38: Global Viral Vectors for Non-human Primates Market Value (US$ Mn), by Gene Therapy, 2020-2034
Figure 39: Global Viral Vectors for Non-human Primates Market Value Share Analysis, by Gene Therapy, 2023 and 2034
Figure 40: Global Viral Vectors for Non-human Primates Market Value (US$ Mn), by Vaccine Research, 2020-2034
Figure 41: Global Viral Vectors for Non-human Primates Market Value Share Analysis, by Vaccine Research, 2023 and 2034
Figure 42: Global Viral Vectors for Non-human Primates Market Value (US$ Mn) Share Analysis, by Therapeutic Area, 2023 and 2034
Figure 43: Global Viral Vectors for Non-human Primates Market Share Analysis, by Therapeutic Area, 2023
Figure 44: Global Viral Vectors for Non-human Primates Market Share Analysis, by Therapeutic Area, 2034
Figure 45: Global Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
Figure 46: Global Viral Vectors for Non-human Primates Market Value (US$ Mn), by Genetic Disorders, 2020-2034
Figure 47: Global Viral Vectors for Non-human Primates Market Value Share Analysis, by Genetic Disorders, 2023 and 2034
Figure 48: Global Viral Vectors for Non-human Primates Market Value (US$ Mn), by Infectious Diseases, 2020-2034
Figure 49: Global Viral Vectors for Non-human Primates Market Value Share Analysis, by Infectious Diseases, 2023 and 2034
Figure 50: Global Viral Vectors for Non-human Primates Market Value (US$ Mn), by Oncological Disorder, 2020-2034
Figure 51: Global Viral Vectors for Non-human Primates Market Value Share Analysis, by Oncological Disorder, 2023 and 2034
Figure 52: Global Viral Vectors for Non-human Primates Market Value (US$ Mn), by Others, 2020-2034
Figure 53: Global Viral Vectors for Non-human Primates Market Value Share Analysis, by Others, 2023 and 2034
Figure 54: Global Viral Vectors for Non-human Primates Market Value (US$ Mn) Share Analysis, by End-user, 2023 and 2034
Figure 55: Global Viral Vectors for Non-human Primates Market Share Analysis, by End-user, 2023
Figure 56: Global Viral Vectors for Non-human Primates Market Share Analysis, by End-user, 2034
Figure 57: Global Viral Vectors for Non-human Primates Market Attractiveness Analysis, by End-user, 2024-2034
Figure 58: Global Viral Vectors for Non-human Primates Market Value (US$ Mn), by Pharmaceutical and Biotechnology Companies, 2020-2034
Figure 59: Global Viral Vectors for Non-human Primates Market Value Share Analysis, by Pharmaceutical and Biotechnology Companies, 2023 and 2034
Figure 60: Global Viral Vectors for Non-human Primates Market Value (US$ Mn), by Academic and Research Institutions, 2020-2034
Figure 61: Global Viral Vectors for Non-human Primates Market Value Share Analysis, by Academic and Research Institutions, 2023 and 2034
Figure 62: Global Viral Vectors for Non-human Primates Market Value Share Analysis, by Region, 2023 and 2034
Figure 63: Global Viral Vectors for Non-human Primates Market Share Analysis, by Region, 2023
Figure 64: Global Viral Vectors for Non-human Primates Market Share Analysis, by Region, 2034
Figure 65: Global Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Region, 2023-2034
Figure 66: North America Viral Vectors for Non-human Primates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 67: North America Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Country, 2024-2034
Figure 68: North America Viral Vectors for Non-human Primates Market Value Share Analysis, by Country, 2023 and 2034
Figure 69: North America Viral Vectors for Non-human Primates Market Value Share Analysis, by Vector Type, 2023 and 2034
Figure 70: North America Viral Vectors for Non-human Primates Market Value Share Analysis, by Type of Non-human Primates, 2023 and 2034
Figure 71: North America Viral Vectors for Non-human Primates Market Value Share Analysis, by Application 2023 and 2034
Figure 72: North America Viral Vectors for Non-human Primates Market Value Share Analysis, by Therapeutic Area, 2023 and 2034
Figure 73: North America Viral Vectors for Non-human Primates Market Value Share Analysis, by End-user, 2023 and 2034
Figure 74: North America Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Vector Type, 2024-2034
Figure 75: North America Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Type of Non-human Primates, 2024-2034
Figure 76: North America Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Application, 2024-2034
Figure 77: North America Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
Figure 78: North America Viral Vectors for Non-human Primates Market Value Share Analysis, by End-user, 2023 and 2034
Figure 79: Europe Viral Vectors for Non-human Primates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 80: Europe Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 81: Europe Viral Vectors for Non-human Primates Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 82: Europe Viral Vectors for Non-human Primates Market Value Share Analysis, by Vector Type, 2023 and 2034
Figure 83: Europe Viral Vectors for Non-human Primates Market Value Share Analysis, by Type of Non-human Primates, 2023 and 2034
Figure 84: Europe Viral Vectors for Non-human Primates Market Value Share Analysis, by Application, 2023 and 2034
Figure 85: Europe Viral Vectors for Non-human Primates Market Value Share Analysis, by Therapeutic Area, 2023 and 2034
Figure 86: Europe Viral Vectors for Non-human Primates Market Value Share Analysis, by End-user, 2023 and 2034
Figure 87: Europe Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Vector Type, 2024-2034
Figure 88: Europe Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Type of Non-human Primates, 2024-2034
Figure 89: Europe Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Application, 2024-2034
Figure 90: Europe Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
Figure 91: Europe Viral Vectors for Non-human Primates Market Attractiveness Analysis, by End-user, 2024-2034
Figure 92: Asia Pacific Viral Vectors for Non-human Primates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 93: Asia Pacific Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 94: Asia Pacific Viral Vectors for Non-human Primates Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 95: Asia Pacific Viral Vectors for Non-human Primates Market Value Share Analysis, by Vector Type, 2023 and 2034
Figure 96: Asia Pacific Viral Vectors for Non-human Primates Market Value Share Analysis, by Type of Non-human Primates, 2023 and 2034
Figure 97: Asia Pacific Viral Vectors for Non-human Primates Market Value Share Analysis, by Application, 2023 and 2034
Figure 98: Asia Pacific Viral Vectors for Non-human Primates Market Value Share Analysis, by Therapeutic Area, 2023 and 2034
Figure 99: Asia Pacific Viral Vectors for Non-human Primates Market Value Share Analysis, by End-user, 2023 and 2034
Figure 100: Asia Pacific Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Vector Type, 2024-2034
Figure 101: Asia Pacific Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Type of Non-human Primates, 2024-2034
Figure 102: Asia Pacific Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Application, 2024-2034
Figure 103: Asia Pacific Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Therapeutic Area, 2023-2034
Figure 104: Asia Pacific Viral Vectors for Non-human Primates Market Attractiveness Analysis, by End-user, 2023-2034
Figure 105: Latin America Viral Vectors for Non-human Primates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 106: Latin America Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 107: Latin America Viral Vectors for Non-human Primates Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 108: Latin America Viral Vectors for Non-human Primates Market Value Share Analysis, by Vector Type, 2023 and 2034
Figure 109: Latin America Viral Vectors for Non-human Primates Market Value Share Analysis, by Type of Non-human Primates, 2023 and 2034
Figure 110: Latin America Viral Vectors for Non-human Primates Market Value Share Analysis, by Application, 2023 and 2034
Figure 111: Latin America Viral Vectors for Non-human Primates Market Value Share Analysis, by Therapeutic Area, 2023 and 2034
Figure 112: Latin America Viral Vectors for Non-human Primates Market Value Share Analysis, by End-user, 2023 and 2034
Figure 113: Latin America Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Vector Type, 2024-2034
Figure 114: Latin America Viral Vectors for Non-human Primates Market Value Share Analysis, by Type of Non-human Primates, 2023 and 2034
Figure 115: Latin America Viral Vectors for Non-human Primates Market Value Share Analysis, by Application, 2023 and 2034
Figure 116: Latin America Viral Vectors for Non-human Primates Market Value Share Analysis, by Therapeutic Area, 2023 and 2034
Figure 117: Latin America Viral Vectors for Non-human Primates Market Value Share Analysis, by End-user, 2023 and 2034
Figure 118: Latin America Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Vector Type, 2024-2034
Figure 119: Latin America Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Type of Non-human Primates, 2024-2034
Figure 120: Latin America Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Application, 2024-2034
Figure 121: Latin America Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
Figure 122: Latin America Viral Vectors for Non-human Primates Market Attractiveness Analysis, by End-user, 2024-2034
Figure 123: Middle East & Africa Viral Vectors for Non-human Primates Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 124: Middle East & Africa Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 125: Middle East & Africa Viral Vectors for Non-human Primates Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 126: Middle East & Africa Viral Vectors for Non-human Primates Market Value Share Analysis, by Vector Type, 2023 and 2034
Figure 127: Middle East & Africa Viral Vectors for Non-human Primates Market Value Share Analysis, by Type of Non-human Primates, 2023 and 2034
Figure 128: Middle East & Africa Viral Vectors for Non-human Primates Market Value Share Analysis, by Application, 2023 and 2034
Figure 129: Middle East & Africa Viral Vectors for Non-human Primates Market Value Share Analysis, by Therapeutic Area, 2023 and 2034
Figure 130: Middle East & Africa Viral Vectors for Non-human Primates Market Value Share Analysis, by End-user, 2023 and 2034
Figure 131: Middle East & Africa Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Vector Type, 2024-2034
Figure 132: Middle East & Africa Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Type of Non-human Primates, 2024-2034
Figure 133: Middle East & Africa Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Application, 2024-2034
Figure 134: Middle East & Africa Viral Vectors for Non-human Primates Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
Figure 135: Middle East & Africa Viral Vectors for Non-human Primates Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Viral Vectors for Non-human Primates Market
